SCHEMBL570154

SCHEMBL570154

Cc1[nH]c2ccccc2c1C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.67
RAB9A P51151 6/20 0.65
KMT2A Q03164 5/20 0.65
ALDH1A1 P00352 5/20 0.65
LMNA P02545 5/20 0.65
MITF O75030 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
KDM4E B2RXH2 3/20 0.62
TDP1 Q9NUW8 1/20 0.62
MAPT P10636 9/20 0.62
NPC1 O15118 5/20 0.62
MEN1 O00255 2/20 0.62
HTT P42858 2/20 0.62
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
GAA P10253 3/20 0.60
PKM P14618 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10513594 0.87 RAB9A (0.65) NR4A2RAB9AKMT2AALDH1A1LMNA
SCHEMBL11063138 0.87 NR4A2 (0.56) NR4A2RAB9AKMT2AALDH1A1LMNA
SCHEMBL27854856 0.86 NR4A2 (0.69) NR4A2RAB9AKMT2AALDH1A1LMNA
SCHEMBL1559343 0.85 NR4A2 (0.63) NR4A2RAB9AKMT2AALDH1A1LMNA
SCHEMBL2355240 0.85 NR4A2 (0.63) NR4A2RAB9AKMT2AALDH1A1LMNA
SCHEMBL5705595 0.85 NR4A2 (0.67) NR4A2RAB9AKMT2AALDH1A1LMNA
SCHEMBL25445916 0.83 NR4A2 (0.65) NR4A2RAB9AKMT2AALDH1A1LMNA
SCHEMBL3624515 0.83 NR4A2 (0.65) NR4A2RAB9AKMT2AALDH1A1LMNA
SCHEMBL591759 0.83 ALDH1A1 (0.68) NR4A2RAB9AKMT2AALDH1A1LMNA
Pyrazinoic Acid SCHEMBL6968007 0.82 KDM4E (0.51) NR4A2RAB9AKMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106083691-B A kind of preparation method of arbidol HCl monohydrate 山东罗欣药业集团恒欣药业有限公司 2018-11-27 CN claimed
EP-2217597-B1 QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE COMENTIS INC (US) 2011-03-30 EP claimed
CN-117756785-A Preparation and application of N- (pyridine-2-yl) benzo [ b ] five-membered heterocycle-3-carboxamide structure compound 江西中医药大学 2024-03-26 CN disclosed
CN-117603123-A Novel indole HDAC6 small molecule inhibitor, preparation method and application 郑州大学 2024-02-27 CN disclosed
US-11891386-B2 Indole compounds and their use ARIAGEN, INC. (CA) 2024-02-06 US disclosed
CN-116964050-A Compounds useful as T cell activators 戈萨默生物服务公司 2023-10-27 CN disclosed
EP-4262986-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS Gossamer Bio Services, Inc. (US) 2023-10-25 EP disclosed
US-20230271954-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES INC (US) 2023-08-31 US disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 EP disclosed
US-20230145074-A1 Indole Compounds and Their Use ARIAGEN, INC. (US) 2023-05-11 US disclosed
US-20230054194-A1 Methods of Treating Cancer ARIAGEN, INC. (US) 2023-02-23 US disclosed
EP-0600955-A1 5-HT4 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-06-15 EP disclosed
EP-0590152-A1 PEPTIDES WITH TACHYKININ ANTAGONIST ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-04-06 EP disclosed
WO-1993003725-A1 5-HT4 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1993-03-04 WO disclosed
WO-1992022569-A1 PEPTIDES WITH TACHYKININ ANTAGONIST ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-12-23 WO disclosed
WO-1992014727-A1 3-PIPERIDINYLMETHYLCARBOXYLATE SUBSTITUTED INDOLES GLAXO GROUP LIMITED (GB) 1992-09-03 WO disclosed
EP-0144986-B1 INDOLE-3-CARBOXAMIDE DERIVATIVES Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1987-03-04 EP disclosed
US-4616009-A PSYCHOLOGICAL DISORDERS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1986-10-07 US disclosed
EP-0144986-A2 Indole-3-carboxamide derivatives Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1985-06-19 EP disclosed
US-3980667-A Anti-arrhythmic 5-endo-substituted oxy-N-(aminoloweralkyl)bicycle [2.2.2.]oc BRISTOL-MYERS COMPANY (US) 1976-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271954-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG NR4A2 2350/4885RAB9A 1071/4885KMT2A 2679/4885
US-11891386-B2 Indole compounds and their use IDO1, IDO2, INMT NR4A2 1539/4885RAB9A 3025/4885KMT2A 1124/4885
US-20230054194-A1 Methods of Treating Cancer TP53, MSH2, PDCD1 NR4A2 3628/4885RAB9A 4066/4885KMT2A 1118/4885
US-20230145074-A1 Indole Compounds and Their Use IDO1, IDO2, INMT NR4A2 1539/4885RAB9A 3025/4885KMT2A 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.